From: Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology
No. | Target | Degree | No. | Target | Degree |
---|---|---|---|---|---|
1 | GAPDH | 77 | 26 | MCL1 | 30 |
2 | ALB | 73 | 27 | LCK | 27 |
3 | TNF | 70 | 28 | PARP1 | 27 |
4 | EGFR | 63 | 29 | GSK3B | 27 |
5 | MAPK1 | 61 | 30 | PIK3R1 | 27 |
6 | CASP3 | 58 | 31 | SERPINE1 | 26 |
7 | STAT3 | 55 | 32 | ABCB1 | 25 |
8 | MAPK8 | 49 | 33 | SYK | 25 |
9 | PTGS2 | 48 | 34 | XIAP | 25 |
10 | JUN | 47 | 35 | SELE | 24 |
11 | IL2 | 43 | 36 | MET | 24 |
12 | ESR1 | 40 | 37 | PRKCA | 24 |
13 | MAPK14 | 40 | 38 | BTK | 23 |
14 | RELA | 39 | 39 | HSPA5 | 23 |
15 | BCL2L1 | 39 | 40 | ABCG2 | 22 |
16 | ICAM1 | 38 | 41 | PRKCB | 22 |
17 | CTNNB1 | 38 | 42 | CD38 | 21 |
18 | MPO | 37 | 43 | AGTR1 | 21 |
19 | FGF2 | 35 | 44 | FLT3 | 20 |
20 | PIK3CA | 34 | 45 | NOS2 | 20 |
21 | CASP8 | 33 | 46 | NFE2L2 | 19 |
22 | ACE | 32 | 47 | ALOX5 | 19 |
23 | F2 | 32 | 48 | CTSB | 18 |
24 | ITGB1 | 32 | 49 | HNF4A | 18 |
25 | PPARG | 31 | 50 | PRKCE | 18 |